How to use Lorlatinib tablets before or after meals

Lorlatinib (Lorlatinib) is an oral prescription drug approved in the United States and Europe for the second- or third-line treatment of ALK-positive metastatic tumors in non-small cell lung cancer (NSCLC). It is the only ALK inhibitor with meaningful activity against the ALK G1202R mutation in lung cancer. Lorlatinib is an anti-cancer drug that needs to be used under the guidance of a doctor. The recommended dose is 100 mg orally taken once a day with or without food until the disease worsens or unacceptable toxicity occurs. Lorlatinib had no clinically significant effect on lorlatinib pharmacokinetics following administration of a high-fat, high-calorie meal (approximately 1,000 calories, with 150 calories from protein, 250 calories from carbohydrates, and 500-600 calories from fat).